SERPINE1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL417709	1.00	16/20
SCHEMBL419189	1.00	15/20
SCHEMBL420979	1.00	15/20
SCHEMBL419585	0.84	15/20
SCHEMBL420745	0.82	15/20
SCHEMBL416776	0.82	15/20
SCHEMBL421057	0.81	15/20
SCHEMBL419028	0.66	15/20
SCHEMBL420923	0.61	15/20
SCHEMBL420035	1.00	14/20
SCHEMBL418257	0.77	14/20
SCHEMBL419586	0.71	14/20
SCHEMBL422130	0.70	14/20
SCHEMBL415975	0.63	14/20
SCHEMBL420890	0.62	14/20
SCHEMBL417478	0.51	14/20
SCHEMBL418836	1.00	13/20
SCHEMBL419036	1.00	13/20
SCHEMBL419193	1.00	13/20
SCHEMBL418648	0.82	13/20

Clinical trials — most relevant to SERPINE1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography	PHASE4	UNKNOWN
Diurnal Variation of Plasminogen Activator Inhibitor-1	PHASE4	COMPLETED
Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency	PHASE4	ACTIVE_NOT_RECRUITING
Atorvastatin in Acute Stroke Treatment	PHASE4	COMPLETED
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults	PHASE3	COMPLETED
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency	PHASE3	COMPLETED
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment	PHASE3	NOT_YET_RECRUITING
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema	PHASE2/PHASE3	COMPLETED
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema	PHASE2/PHASE3	WITHDRAWN
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients	PHASE2/PHASE3	COMPLETED
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery	PHASE1/PHASE2	UNKNOWN
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)	PHASE1/PHASE2	COMPLETED
The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers	PHASE2	COMPLETED
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery	PHASE1	COMPLETED
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	EARLY_PHASE1	UNKNOWN
Surgical Revascularisation and Nerve Stimulation Trial	nan	WITHDRAWN
Belgian Antithrombin Deficiency Registry	nan	NOT_YET_RECRUITING
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors	nan	UNKNOWN
Genetic Architecture of Plasma T-PA and PAI-1	nan	COMPLETED
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence	nan	WITHDRAWN
Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea	nan	COMPLETED
Peripheral Vascular Disease and Nerve Stimulation	nan	COMPLETED
Genomic Research in Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial	nan	COMPLETED
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)	nan	COMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia	nan	COMPLETED
Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a SERPINE1 binder may also engage these)

Protein	Name	Similarity
P79335	—	1.000	P79335 →
P22777	—	1.000	P22777 →
P13909	—	1.000	P13909 →
P50449	—	0.996	P50449 →
P20961	—	0.995	P20961 →
P47776	—	0.985	P47776 →
Q94823	—	0.983	Q94823 →
P07093	—	0.983	P07093 →
P07092	—	0.983	P07092 →
Q9JK88	—	0.983	Q9JK88 →
Q07235	—	0.982	Q07235 →
O75830	—	0.981	O75830 →
P49182	—	0.980	P49182 →
B0UYL8	—	0.980	B0UYL8 →
P05546	—	0.980	P05546 →
P32759	—	0.979	P32759 →
Q64268	—	0.979	Q64268 →
P70458	—	0.978	P70458 →
Q62975	—	0.976	Q62975 →
P32262	—	0.976	P32262 →
P41361	—	0.976	P41361 →
Q7TMF5	—	0.976	Q7TMF5 →
SERPINC1	Antithrombin-III	0.975	landscape →
Q5R5A3	—	0.974	Q5R5A3 →
P32261	—	0.973	P32261 →
Q06B74	—	0.973	Q06B74 →
P19324	—	0.972	P19324 →
Q9V3N1	—	0.972	Q9V3N1 →
A0A0K8RJV9	—	0.971	A0A0K8RJV9 →
Q27086	—	0.971	Q27086 →